Physician profile
Edward D Scheiner
NPI 1184690315
$2,083.30
in general payments reported to CMS, 2019-2025
26 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $88.72 · 2021: $51.94 · 2022: $352 · 2023: $595 · 2024: $524 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $542.06 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $315.78 | 2020-2025 | |
| Csl Behring | $186.97 | 2023-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $165.59 | 2019-2022 | |
| Optinose US, INC. | $125.25 | 2019-2025 | |
| Alk-Abello, INC | $107.61 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Medtronic USA, INC. | $94.97 | 2019 | |
| Amgen INC. | $77.52 | 2022-2023 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $60.02 | 2024-2025 | Tezspire |
| Acclarent, INC | $46.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.86 | 2023-2025 | Hyqvia, Takhzyro |
| Incyte Corporation | $33.19 | 2025 | Opzelura |
| Hikma Pharmaceuticals USA | $29.41 | 2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $28.91 | 2022-2023 | Airduo Digihaler |
| Inspire Medical Systems, INC. | $24.83 | 2023 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24.31 | 2023 | Ligasure |
| Greer Laboratories, INC. | $23.83 | 2023 | Oralair |
| Stryker Corporation | $22.98 | 2022 | |
| Acera Surgical, INC. | $22.23 | 2024 | Restrata Wound Matrix |
| Novartis Pharmaceuticals Corporation | $19.90 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $17.00 | 2025 | Neffy |
| Genentech USA, INC. | $16.90 | 2024 | Xolair |
| Kaleo, INC. | $14.99 | 2022 | |
| Merck Sharp & Dohme LLC | $14.99 | 2023 | |
| Pharming Healthcare, INC. | $13.54 | 2022 | |
| Intersect Ent, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Scheiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.